<DOC>
	<DOC>NCT01634282</DOC>
	<brief_summary>The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate the efficacy of OPC-262</brief_summary>
	<brief_title>Along-term Study of OPC-262 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients who completed Study 26209001 (namely, patients who visited the hospital at visit Week 24ï¼‰ Patients who are capable of giving informed consent prior to participating in this clinical study Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the postobservation period) Patients who withdrew from Study 26209001 Patients who experienced serious adverse events that the relationship with the study drug was not denied in Study 26209001 Patients who experienced serious adverse events that the relationship with the study drug are denied in Study 26209001 and whose symptoms are still emerged at the time of initiation of this study Patients who met the exclusion criteria of Study 26209001 during the study period of Study 26209001 Female patients who wish to become pregnant during the study period of Study 26209002 or within 4 weeks after the study Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>